Under FDA Circular 2021-008 or the Updated Guidelines for the Registration of Drug Products Under Emergency Use (DEU) for COVID-19, licensed drug establishments intending to manufacture and import/ distribute drug products listed in the Philippine COVID-19 Living Recommendations may register as DEU provided that such drug products have a positive recommendation and a registered counterpart with the FDA at the time of the application.
As of 2 September 2021, the following products may be registered as Drug Products under Emergency Use (DEU) for COVID-19:
Generic Name | Strength | Dosage Form |
Tocilizumab | 400 mg/ 20 mL | Concentrate Solution for Infusion (IV) |
80 mg/ 4 mL (20 mg/mL) | Concentrate Solution for Infusion (IV) | |
200 mg/ 10 mL | Concentrate Solution for Infusion (IV) | |
Baricitinib | 2 mg | Tablet |
4 mg | Tablet | |
Dexamethasone (as sodium phosphate) | 4 mg/mL | Solution for Injection (IM/IV) |
50 mg/mL | Solution for Injection (IM/IV) | |
4 mg/mL (8 mg/ 2 mL) | Solution for Injection (IM/IV) | |
5 mg/ mL | Solution for Injection (IM/IV) | |
2 mg/mL | Solution for Injection (IM/IV) | |
Heparin Sodium | 5,000 IU/ mL (25,000 IU/ 5mL) | Solution for Injection (IV/SC) |
1,000 IU/ mL (5,000 IU/ 5mL) | Solution for Injection (IV/SC) | |
1000 IU/ mL | Solution for Injection (IV/SC) | |
5000 IU/mL | Solution for Injection (IV/SC)
|
|
Enoxaparin Sodium | 60mg/0.6mL | Solution For Injection (SC) |
40 mg/0.4 mL | Solution for Injection (SC) | |
4,000 IU Anti-Factor Xa (equivalent to 40mg) / 0.4mL | Solution for Injection (IV/SC) | |
2,000 IU Anti-Factor Xa (equivalent to 20mg) / 0.2mL | Solution for Injection (IV/SC) | |
6,000 IU Anti-Factor Xa (equivalent to 60mg) / 0.6mL | Solution for Injection (IV/SC) | |
20mg/ 0.2mL | Solution for Injection (IV/SC) | |
Bivalirudin | 250 mg | Lyophilized Powder for Injection (I.V.) |
Tinzaparin sodium | 10000 anti-Xa IU/mL | Solution For Injection (SC) |
Dalteparin Sodium | 2500 I.U/0.2 mL Solution | Solution For Injection In Pre-Filled Syringe |
For the information and guidance of all.